25.61

14.61% -4.43

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $25.61, with a volume of 1.87M. It is down -14.61% in the last 24 hours and up +0.35% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$30.04

Open:

$29.3

24h Volume:

1.87M

Relative Volume:

1.68

Market Cap:

$1.41B

Revenue:

$199.89M

Net Income/Loss:

$52.48M

P/E Ratio:

30.13

EPS:

0.85

Net Cash Flow:

$61.15M

1W Performance:

-22.27%

1M Performance:

+0.35%

6M Performance:

+166.36%

1Y Performance:

+99.46%

1-Day Range:

$24.50

$29.44

1-Week Range:

$24.50

$33.13

52-Week Range:

$5.35

$38.69

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1139)

Industry

Biotechnology (635)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

128

Twitter

@stoketx

Next Earnings Date

2025-03-18

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	25.65	1.65B	199.89M	52.48M	61.15M	0.85
VRTX Vertex Pharmaceuticals Inc	423.48	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	639.93	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	430.94	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	823.90	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	185.96	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

11:35 AM

Stoke Therapeutics (STOK): JP Morgan Raises Price Target, Mainta - GuruFocus

11:35 AM

09:14 AM

Live market analysis of Stoke Therapeutics Inc.Buy Signal & Stock Portfolio Risk Management - newser.com

09:14 AM

08:45 AM

Why Stoke Therapeutics Inc. stock attracts high net worth investorsQuarterly Growth Report & Free Expert Verified Stock Movement Alerts - newser.com

08:45 AM

08:15 AM

Can Stoke Therapeutics Inc. stock sustain institutional interestMarket Activity Summary & Daily Momentum Trading Reports - newser.com

08:15 AM

05:17 AM

Using portfolio simulators with Stoke Therapeutics Inc. includedJuly 2025 Institutional & Safe Capital Investment Plans - newser.com

05:17 AM

04:46 AM

What technical models suggest about Stoke Therapeutics Inc.’s comebackJuly 2025 Highlights & Risk Managed Investment Strategies - newser.com

04:46 AM

04:22 AM

What insider trading reveals about Stoke Therapeutics Inc. stockJuly 2025 Chart Watch & Low Drawdown Momentum Trade Ideas - newser.com

04:22 AM

12:51 PM

Will Stoke Therapeutics Inc. stock maintain momentum in 2025Market Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com

12:51 PM

Nov 02, 2025

Does Stoke Therapeutics Inc. show high probability of rebound2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com

Nov 02, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 02, 2025

Nov 01, 2025

Stoke Therapeutics Shares Plunge Following Clinical Trial Data Release - AD HOC NEWS

Nov 01, 2025

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.3%Should You Sell? - MarketBeat

Nov 01, 2025

Is Stoke Therapeutics Inc. stock a good choice for value investorsTrade Entry Report & Short-Term Trading Opportunity Alerts - newser.com

Nov 01, 2025

Oct 31, 2025

Stoke Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView

Oct 31, 2025

Exit strategy if you’re trapped in Stoke Therapeutics Inc.July 2025 Macro Moves & Weekly High Return Opportunities - newser.com

Oct 31, 2025

Oct 30, 2025